Resistant hypertension - Progress in diagnosis and treatment;Oporne nadciśnienie tȩtnicze - Postȩpy w diagnostyce i leczeniu

Kardiologia Polska

Volumn 70, Issue 1, 2012, Pages 66-74

  Szwench, Elzbieta ^a   Florczak, Elzbieta ^a   Prejbisz, Aleksander ^a   Ka̧dziela, Jacek ^a   Witkowski, Adam ^a   Januszewicz, Andrzej ^a  

^a INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

HYPERTENSION; REVIEW; BLOOD PRESSURE; BLOOD PRESSURE MEASUREMENT; DRUG EFFECT; HOSPITALIZATION; HUMAN; PHYSIOLOGY;

ALDOSTERONE ANTAGONIST; ANTIHYPERTENSIVE AGENT;

ALDOSTERONE ANTAGONISTS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE DETERMINATION; HUMANS; HYPERTENSION; SEVERITY OF ILLNESS INDEX;

EID: 84856282194     PISSN: 00229032     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Kaplan NM. Resistant hypertension. J Hypertens, 2005; 23: 1441-1444. (Pubitemid 41104810)
2. Januszewicz A, Prejbisz A. Oporne nadciśnienie tȩtnicze. Zasady postȩpowania w praktyce lekarskiej. Via Medica, Gdańsk, 2009.
3. Williams B. Resistant hypertension: an unmet treatment need. Lancet, 2009; 374: 1396-1398.
4. Alderman MH. Resistant hypertension: a clinical syndrome in search of a definition. Am J Hypertens, 2008; 21: 965-966.
5. Zasady postȩpowania w nadciśnieniu tȩtniczym - 2008 rok. Wytyczne Polskiego Towarzystwa Nadciśnienia Tȩtniczego oraz Kolegium Lekarzy Rodzinnych w Polsce. Nadciśnienie Tȩtnicze, 2008; 12: C1-C30.
6. Calhoun DA, Jones D, Textor S et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension, 2008; 51: 1403-1419.
7. Mancia G, De Backer G, Dominiczak A et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens, 2007; 25: 1105-1187. (Pubitemid 46924065)
8. Mancia G, Laurent S, Agabiti-Rosei E et al. Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens, 2009; 27: 2121-2158.
9. Egan BM, Zhao Y, Axon RN. US trends in prevalence, awareness, treatment, and control of hypertension, 1988-2008. JAMA, 2010; 303: 2043-2050.
10. McAdam-Marx C, Ye X, Sung JC, Brixner DI, Kahler KH. Results of a retrospective, observational pilot study using electronic medical records to assess the prevalence and characteristics of patients with resistant hypertension in an ambulatory care setting. Clin Therapeut, 2009; 31: 1116-1123.
11. de la Sierra A, Segura J, Banegas JR et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension, 2011; 57: 898-902.
12. Yakovlevitch M, Black HR. Resistant hypertension in a tertiary care clinic. Arch Internal Med, 1991; 151: 1786-1792.
13. Garg JP, Elliott WJ, Folker A, Izhar M, Black HR. Resistant hypertension revisited: a comparison of two university-based cohorts. Am J Hypertens, 2005; 18: 619-626. (Pubitemid 40692429)
14. Knight EL, Bohn RL, Wang PS, Glynn RJ, Mogun H, Avorn J. Predictors of uncontrolled hypertension in ambulatory patients. Hypertension, 2001; 38: 809-814. (Pubitemid 34258675)
15. Florczak E, Januszewicz A, Prejbisz A et al. Frequency of obturative sleep apnea and other common secondary hypertension causes in patients with true resistant hypertension. J Hypertens, 2010; 28: e536-e537.
16. Pepin JL, Borel AL, Baguet JP, Tamisier R, Levy P, Mallion JP. Hypertension and sleep. European Society of Hypertension Scientific Newsletter, 2010; 11: No. 46.
17. Muxfeldt ES, Cardoso CR, Dias VB, Nascimento AC, Salles GF. Prognostic impact of the ambulatory arterial stiffness index in resistant hypertension. J Hypertens, 2010; 28: 1547-1553.
18. Stergiou GS, Siontis KC, Ioannidis JP. Home blood pressure as a cardiovascular outcome predictor: it's time to take this method seriously. Hypertension, 2010; 55: 1301-1303.
19. Fan HQ, Li Y, Thijs L et al. Prognostic value of isolated nocturnal hypertension on ambulatory measurement in 8711 individuals from 10 populations. J Hypertens, 2010; 28: 2036-2045.
20. Agarwal R, Bills JE, Hecht TJ, Light RP. Role of home blood pressure monitoring in overcoming therapeutic inertia and improving hypertension control: a systematic review and metaanalysis. Hypertension, 2010; 57: 29-38.
21. Parati G, Stergiou GS, Asmar R et al. European Society of Hypertension practice guidelines for home blood pressure monitoring. J Human Hypertens, 2010; 24: 779-785.
22. Pimenta E, Gaddam KK, Oparil S et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension, 2009; 54: 475-481.
23. Chapman N, Dobson J, Wilson S et al. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension, 2007; 49: 839-845. (Pubitemid 351664214)
24. Eze-Nliam CM, Thombs BD, Lima BB, Smith CG, Ziegelstein RC. The association of depression with adherence to antihypertensive medications: a systematic review. J Hypertens, 2010; 28: 1785-1795.
25. Calhoun DA. Low-dose aldosterone blockade as a new treatment paradigm for controlling resistant hypertension. J Clin Hypertens (Greenwich, Conn), 2007; 9: 19-24.
26. Parthasarathy HK, Alhashmi K, McMahon AD et al. Does the ratio of serum aldosterone to plasma renin activity predict the efficacy of diuretics in hypertension? Results of RENALDO. J Hypertens, 2010; 28: 170-177.
27. Wolk R, Shamsuzzaman AS, Somers VK. Obesity, sleep apnea, and hypertension. Hypertension, 2003; 42: 1067-1074. (Pubitemid 37549057)
28. Farsang C, Naditch-Brule L, Perlini S, Zidek W, Kjeldsen SE. Inter-regional comparisons of the prevalence of cardiometabolic risk factors in patients with hypertension in Europe: the GOOD survey. J Human Hypertens, 2009; 23: 316-324.
29. Sowers JR, Whaley-Connell A, Epstein M. Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension. Ann Intern Med, 2009; 150: 776-783.
30. Douma S, Petidis K, Doumas M et al. Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet, 2008; 371: 1921-1926. (Pubitemid 351778191)
31. Calhoun DA, Nishizaka MK, Zaman MA, Thakkar RB, Weissmann P. Hyperaldosteronism among black and white subjects with resistant hypertension. Hypertension, 2002; 40: 892-896. (Pubitemid 35434912)
32. Gallay BJ, Ahmad S, Xu L, Toivola B, Davidson RC. Screening for primary aldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis, 2001; 37: 699-705. (Pubitemid 32268029)
33. Eide IK, Torjesen PA, Drolsum A, Babovic A, Lilledahl NP. Low-renin status in therapy-resistant hypertension: a clue to efficient treatment. J Hypertens, 2004; 22: 2217-2226. (Pubitemid 39463817)
34. Umpierrez GE, Cantey P, Smiley D et al. Primary aldosteronism in diabetic subjects with resistant hypertension. Diabetes Care, 2007; 30: 1699-1703. (Pubitemid 47036339)
35. Pimenta E, Calhoun DA. Resistant hypertension and aldosteronism. Curr Hypertens Reports, 2007; 9: 353-359. (Pubitemid 350226317)
36. Ruttanaumpawan P, Nopmaneejumruslers C, Logan AG, Lazarescu A, Qian I, Bradley TD. Association between refractory hypertension and obstructive sleep apnea. J Hypertens, 2009; 27: 1439-1445.
37. Friedman O, Bradley TD, Ruttanaumpawan P, Logan AG. Independent association of drug-resistant hypertension to reduced sleep duration and efficiency. Am J Hypertens, 2010; 23: 174-179.
38. Lozano L, Tovar JL, Sampol G et al. Continuous positive airway pressure treatment in sleep apnea patients with resistant hypertension: a randomized, controlled trial. J Hypertens, 2010; 28: 2161-2168.
39. Gaddam K, Pimenta E, Thomas SJ et al. Spironolactone reduces severity of obstructive sleep apnoea in patients with resistant hypertension: a preliminary report. J Human Hypertens, 2010; 24: 532-537.
40. Kadziela J, Florczak E, Januszewicz A, Witkowski A. Denerwacja nerek - nowa metoda leczenia opornego nadciśnienia tȩtniczego. Post Kardiol Interw, 2010; 6: 173-176.
41. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet, 2009; 373: 1275-1281.
42. Esler MD, Krum H, Sobotka PA, Schlaich MP, Schmieder RE, Bohm M. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet, 2010; 376: 1903-1909.
43. Witkowski A, Prejbisz A, Florczak E et al. Effects of renal sympathetic denervation on blood pressure, sleep apnea course, and glycemic control in patients with resistant hypertension and sleep apnea. Hypertension, 2011; 58: 559-565.
44. Witkowski A, Januszewicz A, Imiela J et al. Stanowisko grupy ekspertów w sprawie zabiegów przezskórnej denerwacji nerek w leczeniu nadciśnienia tȩtniczego w Polsce. Kardiol Pol, 2011; 69: 1208-1211.
45. Mancia G, Parati G, Zanchetti A. Electrical carotid baroreceptor stimulation in resistant hypertension. Hypertension, 2010; 55: 607-609.
46. Bisognano JD, Bakris G, Nadim MK et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol, 2011; 58: 765-773.
47. Scheffers IJ, Kroon AA, Schmidli J et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol, 2010; 56: 1254-1258.
48. Weber MA, Black H, Bakris G et al. A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial. Lancet, 2009; 374: 1423-1431.
49. Tissot AC, Maurer P, Nussberger J et al. Effect of immunisation against angiotensin II with CYT006-AngQb on ambulatory blood pressure: a double-blind, randomised, placebo-controlled phase IIa study. Lancet, 2008; 371: 821-827. (Pubitemid 351323893)
50. Cecelja M, Chowienczyk P. Arterial stiffening: cause and prevention. Hypertension, 2010; 56: 29-30.
51. McManus RJ, Mant J, Bray EP et al. Telemonitoring and self-management in the control of hypertension (TASMINH2): a randomised controlled trial. Lancet, 2010; 376: 163-172.